Oryzon Genomics, a CataloniaBio & HealthTech member, has received approval from the Spanish Drug Agency (AEMPS) under certain urgency provisions to conduct a Phase II clinical trial with vafidemstat in seriously ill Covid-19 patients.
The study ESCAPE is an open-label, randomized and double-arm trial to assess the efficacy and tolerability of vafidemstat in combination with standard of care treatment, to prevent progression to Acute Respiratory Distress Syndrome (ARDS).
Initially, it is planned to include 20 patients in each arm of the trial at Hospital Vall d'Hebron and Hospital del Mar, both in Barcelona. More centers can be added if is necessary.
Comments